Bank of Nova Scotia (NYSE:BNS) has hired Matt Eilers, a former executive at UBS Group (UBS), as it its new co-head of ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Jeff Zuckerman has returned to Tourmaline as a Managing Director where he will oversee senior trading responsibilities. He is a veteran of Blackstone, Deutsche Bank, and Ziff Brothers. Zuckerman ...

Scotiabank lowered the firm’s price target on Hudbay Minerals (HBM) to C$12 from C$13.50 and keeps an Outperform rating on the shares.Don't ...

We recently published a list of Top 10 Stocks to Watch as Investors Brace for Potential Recession. In this article, we are ...

Edgewise Therapeutics (NASDAQ:EWTX) was downgraded to Sector Perform from prior Sector Outperform at Scotiabank after results ...

After ending 2024 on a solid note with 20% gains, Bank of Nova Scotia ( TSX:BNS ), or Scotiabank, has turned volatile in 2025 ...

Stock analysts at Scotiabank cut their FY2025 EPS estimates for Lithium Americas in a report released on Monday, March 31st. Scotiabank analyst B. Isaacson now anticipates that the company will earn ...

Equities research analysts at Scotiabank dropped their FY2025 earnings per share (EPS) estimates for Lithium Americas in a research note issued on Monday, March 31st. Scotiabank analyst B. Isaacson ...

Global Equity Research announced adjustments to its equity ratings, responding to the recent imposition of broad tariffs by the US administration. While most countries are affected by these tariffs, ...

Bank of America Securities downgraded the Bank of Nova Scotia (NYSE:BNS), known as Scotiabank, to Neutral from Buy as its operating outlook shifts from increased trade tensions. The bank's heavy ...